Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Aziyo Biologics (ELUT) and Ironwood Pharma (IRWD)

Tipranks - Tipranks - Tue Nov 11, 2025

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Genmab (GMAB – Research Report), Aziyo Biologics (ELUT – Research Report) and Ironwood Pharma (IRWD – Research Report).

Meet Your ETF AI Analyst

Genmab (GMAB)

In a report issued on November 7, Yaron Werber from TD Cowen maintained a Hold rating on Genmab, with a price target of $32.00. The company’s shares closed last Monday at $29.28, close to its 52-week high of $30.56.

According to TipRanks.com, Werber is a 5-star analyst with an average return of 20.3% and a 60.4% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Ionis Pharmaceuticals, and Dianthus Therapeutics. ;'>

Genmab has an analyst consensus of Moderate Buy, with a price target consensus of $41.00.

See Insiders’ Hot Stocks on TipRanks >>

Aziyo Biologics (ELUT)

Lake Street analyst Frank Takkinen reiterated a Buy rating on Aziyo Biologics on November 7 and set a price target of $5.00. The company’s shares closed last Monday at $0.94.

According to TipRanks.com, Takkinen is a 3-star analyst with an average return of 2.4% and a 41.0% success rate. Takkinen covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., Inspire Medical Systems, and TriSalus Life Sciences. ;'>

Aziyo Biologics has an analyst consensus of Moderate Buy, with a price target consensus of $3.50, representing a 302.8% upside. In a report issued on November 7, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $2.00 price target.

Ironwood Pharma (IRWD)

Craig-Hallum analyst Chase Knickerbocker assigned a Hold rating to Ironwood Pharma today. The company’s shares closed last Monday at $2.44, close to its 52-week low of $1.34.

According to TipRanks.com, Knickerbocker is a top 100 analyst with an average return of 34.6% and a 62.2% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Xtant Medical Holdings, and Diamedica Therapeutics. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Ironwood Pharma.

Read More on GMAB:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).